Patent · US Active

Antibody recognizing N-domain of midkine

US9624294B2 · kind B2 · utility

0Cited by
13References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 13, 2012
Grant dateApr 18, 2017
Priority date
Expiry dateDec 23, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to isolated or recombinant proteins, such as antibodies, which inhibit or reduce the function of midkine (hereinafter, referred to as “MK”) for use in the treatment or prevention of midkine-related disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.